

Lockington, Elliott (SPAC/PSPC)

From: jeevan@numed.io
Sent: July 15, 2020 2:56 PM
To: Kusnick, Chelsea (SPAC/PSPC)
Subject: RE: Remdesivir

Ok. Thank you.

On Jul. 15, 2020 2:50 p.m., "Kusnick, Chelsea (SPAC/PSPC)" <chelsea.kusnick@canada.ca> wrote:

So we are interested in it, but it hasn't yet been approved in Canada. Please speak with Alain for further details.

Thanks,

Chelsea

From: jeevan@numed.io [mailto:jeevan@numed.io]
Sent: July 15, 2020 1:48 PM
To: Kusnick, Chelsea (SPAC/PSPC) <chelsea.kusnick@canada.ca>
Subject: RE: Remdesivir

Thank you.

On Jul. 15, 2020 9:03 a.m., "Kusnick, Chelsea (SPAC/PSPC)" <chelsea.kusnick@canada.ca> wrote:

I'll check, but I don't believe we are looking to procure it at the moment.

From: Jeevan Singh [mailto:jeevan@numed.io]
Sent: July 15, 2020 2:32 AM
To: Kusnick, Chelsea (SPAC/PSPC) <chelsea.kusnick@canada.ca>
Subject: Remdesivir

Hi Chelsea,

could you please do me a favor. Can you please let me know or find out if we are looking for remdesivir or are we waiting until Canadian clinical trials end to make a decision?

Beximco Pharma produces the generic version of it. My friends company Biocare has got the contract to market it in the Philippines. We are engaging Beximco directly to get the rights to the Canadian market. Should we fail, we will run things through Biocare. Either way, don't worry about the shortage the USA has caused, I am putting us in a position to get it should we need it.

cheers

J

Best Regards,

Jeevan Singh

Email: Jeevan@numed.io

Direct: +1 (613) 8944819



This email is confidential and is intended for the exclusive use of the addressee. Any other person is strictly prohibited from disclosing, distributing or reproducing it. If you have received this email by mistake please notify the sender and delete all copies.